N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=58 Allergy Immunotherapy for the Reduction of Asthma
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
Phase 3 N=421 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
Phase 3 N=211 Characterization of the Role of Histamine in Children With Asthma
Asthma · Allergic Asthma · Non-allergic Asthma
Primary: Characterize Contribution of Histamine in Children With Asthma — 11253.24; 6464.20; 3539.67 flux units on a continuous scale
Phase 2 N=24 A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics
Asthma
Primary: Late Asthmatic Response (LAR): Minimum FEV1 Between 4-10 Hours After Allergen Challenge on Day 13 of Each Treatment Period — -0.903; -0.663; -0.638; -0.446 Liters
Phase 2 N=28 Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
Asthma
Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…
Phase 4 N=313 Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
Asthma
Primary: Asthma Control — 312; 72; 0; 229 Participants
Phase 3 N=46 Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
Asthma
Primary: Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge — 0.822; 6.468 Percent — p=0.0208
Phase 2 N=24 The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
Atopic Asthma
Primary: Baseline Percentage of Eosinophils Recovered in the BAL Prior to Segmental Allergen Challenge — 42; 19 percentage of cells
Phase 4 N=406 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Asthma
Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants
Phase 2 N=18 Biomarkers of Irritant-Induced and Allergic Asthma
Asthma
Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change
N/A N=33 Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics
Allergic Asthma
Primary: Effect of Natural-source d-α-tocopheryl Acetate on the Baseline and Allergen-induced Levels of F2-isoprostanes in the Bronchoalveolar Lavage Fluid (BAL)
Phase 3 N=628 Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
Asthma
Primary: Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid Treatment Period — 0.45; 0.64 Exacerbations per patient per 24-weeks
Phase 2 N=36 Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
Asthma
Primary: Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum Forced Expiratory Volume in 1 Second (FEV1) Between 4-10 Hours Following Allergen Challenge One…
Phase 4 N=271 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
Persistent Allergic Asthma
Primary: Change From Baseline in Asthma Control Test (ACT) After 24 Weeks of Treatment — 5.2; 4.7 Score on a scale
Phase 2 N=12 Subcutaneous Immunotherapy for Mouse in Adults
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events
Phase 4 N=275 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
Allergic Asthma
Primary: Number of Participants With Systemic Allergic Reactions (SAR) to Specific Immunotherapy (SIT) — 32; 17; 49 participants
Early Phase 1 N=9 In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma
Asthma
Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…
Phase 3 N=41 Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
Asthma
Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI
Phase 2 N=51 Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study
Asthma · Allergic Sensitization
Primary: Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion — 22; 19 participants — p=0.28
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
N/A N=351 Allergens in Inner-City Schools and Childhood Asthma
Asthma
Primary: Maximum Symptom Days/14 Days — 2.7 days
Phase 4 N=725 Study Of Allergic Rhinitis In Patients Who Also Have Asthma
Asthma
Primary: Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population — 26.4; 3.6 L/min — p=<0.001
Phase 2 N=27 Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Asthma
Primary: Maximum Percent Drop From Pre-allergen Baseline in Forced Expiratory Volume in 1 Second (FEV1) for Late-Phase Asthma Response (LAR) at Screening — 27.19; 20.47 percent…
Phase 4 N=36 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
Allergic Asthma
Primary: Change From Baseline in Total Subepithelial Eosinophils at the End of Week 78 (End of Treatment) — -5.807; -5.890; 1.555; -5.626 cells/mm^2
Phase 2 N=61 A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
Allergic Asthma
Primary: Change in Logarithmically Transformed (log2) Allergen PC15 Concentration (Allergen Concentration Required to Evoke a 15% Decrease in FEV1) — 1.15; 1.85; 0.36…
Phase 2 N=20 The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen
Asthma
Primary: Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1 — 90.97; 91.32; 87.28…
Phase 2 N=9 The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
Allergic Asthma
Primary: FEV1, Late Asthmatic Response (LAR) - Pre-treatment — 0.814; 1.01 ratio
Phase 3 N=30 The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma
Rhinitis · Asthma · Allergy
Primary: Change in Symptoms Score After Nasal Allergen Challenge — -5; -4; -1 score on a scale